Dr. Ronald Eugene Bost, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 50 Stoney Brook Rd, Shavertown, PA 18708 Phone: 570-696-4869 Fax: 570-696-4869 |
News Archive
Indiana University cancer researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for those with an aggressive form of breast cancer.
Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.
Using a "systems biology" approach - which focuses on understanding the complex relationships between biological systems - to look under the hood of an aggressive form of breast cancer, researchers for the first time have identified a set of proteins in the blood that change in abundance long before the cancer is clinically detectable.
Bayfront Medical Center has selected Clinical Xpert CareFocus from Thomson Reuters as its clinical surveillance solution for improving Core Measures outcomes and patient safety indicator (PSI) scores while also supporting infection control and pharmacy intervention initiatives.
› Verified 5 days ago